Related Experiment Video

Updated: Jun 16, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

A novel histone deacetylase inhibitor prevents IL-1beta induced metabolic dysfunction in pancreatic beta-cells

Laura Susick1, Thulani Senanayake, Rajakrishnan Veluthakal

  • 1Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.

Journal of Cellular and Molecular Medicine
|February 10, 2010
PubMed

Insights

Novel histone deacetylase (HDAC) inhibitors show promise in protecting beta-cells from inflammatory damage. Compound THS-78-5 effectively prevented IL-1beta-induced cell death and reduced nitric oxide production, suggesting therapeutic potential for autoimmune diabetes.

Area of Science:

  • Immunology
  • Endocrinology
  • Molecular Biology

Background:

  • Cytokines like IL-1beta induce beta-cell damage, contributing to autoimmune diabetes.
  • Histone deacetylase (HDAC) inhibitors can mitigate some cytokine effects but may have cytotoxicity.
  • Novel HDAC inhibitors are needed for effective beta-cell protection.

Purpose of the Study:

  • To investigate novel HDAC inhibitors for cytoprotective effects against IL-1beta-induced damage in isolated beta-cells.
  • To identify compounds that inhibit HDAC activity without causing cytotoxicity.
  • To evaluate the efficacy of promising compounds in preventing beta-cell death and associated inflammatory pathways.

Main Methods:

  • Screening of novel HDAC inhibitors (THS-73-44, THS-72-5, THS-78-5) for activity against IL-1beta-treated isolated beta-cells.
  • Assessing HDAC inhibition and histone H4 acetylation.
  • Evaluating compound cytotoxicity on metabolic cell viability.
  • Measuring protection against IL-1beta-mediated loss in beta-cell viability.
  • Analyzing effects on inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) release.
  • Investigating the impact on nuclear factor kappaB (NF-kappaB) transactivation.

Main Results:

  • Three novel compounds (THS-73-44, THS-72-5, THS-78-5) inhibited HDAC activity and increased histone H4 acetylation.
  • These compounds exhibited no toxic effects on beta-cell metabolic viability.
  • Only THS-78-5 demonstrated significant protection against IL-1beta-induced beta-cell death.
  • THS-78-5 attenuated IL-1beta-induced iNOS expression and subsequent NO release.
  • THS-78-5 partially inhibited IL-1beta-induced NF-kappaB transactivation.

Conclusions:

  • THS-78-5 is a novel HDAC inhibitor with significant cytoprotective potential against IL-1beta-mediated damage in isolated beta-cells.
  • THS-78-5's protective effects may involve the inhibition of iNOS and NF-kappaB pathways.
  • These findings suggest THS-78-5 as a potential therapeutic candidate for preventing cytokine-induced beta-cell dysfunction and autoimmune diabetes.

More Related Videos

Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...